American Tower REIT Stock Climbs 9.3%, Outperforms Market
Dow Jones2026/10/09 20:33This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of American Tower REIT advanced 9.3% to $182.24 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.6% to 7,811.54 and the Dow Jones Industrial Average rising 0.8% to 51,654.95. This was the stock's sixth consecutive day of gains. American Tower REIT closed 7.1% below its 52-week high of $196.08, which the company achieved on June 5th. The stock demonstrated a mixed performance when compared to some of its peers, as Crown Castle Inc. rose 15.6% to $79.64, SBA Communications Corp. rose 7.3% to $182.49. Trading volume totaled 8.5 million, compared to the 50-day average of 2.5 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 09, 2026 16:33 ET (20:33 GMT)
This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of American Tower REIT advanced 9.3% to $182.24 on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.6% to 7,811.54 and the Dow Jones Industrial Average rising 0.8% to 51,654.95.
This was the stock's sixth consecutive day of gains.
American Tower REIT closed 7.1% below its 52-week high of $196.08, which the company achieved on June 5th.
The stock demonstrated a mixed performance when compared to some of its peers, as Crown Castle Inc. rose 15.6% to $79.64, SBA Communications Corp. rose 7.3% to $182.49.
Trading volume totaled 8.5 million, compared to the 50-day average of 2.5 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 09, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
JPMorgan raises AbbVie target price to $300